[Short and intermediate-term hemodynamic study at rest and during exercise of cardiac insufficiency treated by captopril]. 1986

A Chabanier, and A Richard, and P Virot, and T Bontemps, and A Tardieu, and D Pinaud, and H Vergnoux, and P Blanc, and J Bensaïd

Administration of 25 mg of captopril to 10 patients with heart failure (NYHA II, III) produces at rest after 60 min bradycardia (-7 per cent, p less than 0.01), hypotension (-8 per cent) and improvement of the preload (-30 per cent, p less than 0.01). This effect is still apparent after two months of treatment where PAP is decreased by 20 per cent (p less than 0.05). A prolonged effect of captopril is present in these 10 patients. The capacity to perform a muscular exercise on an ergometric bicycle is prolonged by 10 per cent (p less than 0.01) on the first day and by 18 per cent (p less than 0.01) after two months of treatment. This improvement seems to be related to improvement of the hemodynamic parameters, especially of preload indices. In 5 patients, lactacidemia, the arterio-venous difference and the extraction coefficient of O2 were studied at rest and during exercise. No significant difference are noted after the treatment with the inhibitors of conversion enzymes.

UI MeSH Term Description Entries
D007773 Lactates Salts or esters of LACTIC ACID containing the general formula CH3CHOHCOOR.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012146 Rest Freedom from activity. Rests
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D004452 Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Echocardiography, Contrast,Echocardiography, Cross-Sectional,Echocardiography, M-Mode,Echocardiography, Transthoracic,Echocardiography, Two-Dimensional,Transthoracic Echocardiography,2-D Echocardiography,2D Echocardiography,Contrast Echocardiography,Cross-Sectional Echocardiography,Echocardiography, 2-D,Echocardiography, 2D,M-Mode Echocardiography,Two-Dimensional Echocardiography,2 D Echocardiography,Cross Sectional Echocardiography,Echocardiography, 2 D,Echocardiography, Cross Sectional,Echocardiography, M Mode,Echocardiography, Two Dimensional,M Mode Echocardiography,Two Dimensional Echocardiography
D005080 Exercise Test Controlled physical activity which is performed in order to allow assessment of physiological functions, particularly cardiovascular and pulmonary, but also aerobic capacity. Maximal (most intense) exercise is usually required but submaximal exercise is also used. Arm Ergometry Test,Bicycle Ergometry Test,Cardiopulmonary Exercise Testing,Exercise Testing,Step Test,Stress Test,Treadmill Test,Cardiopulmonary Exercise Test,EuroFit Tests,Eurofit Test Battery,European Fitness Testing Battery,Fitness Testing,Physical Fitness Testing,Arm Ergometry Tests,Bicycle Ergometry Tests,Cardiopulmonary Exercise Tests,Ergometry Test, Arm,Ergometry Test, Bicycle,Ergometry Tests, Arm,Ergometry Tests, Bicycle,EuroFit Test,Eurofit Test Batteries,Exercise Test, Cardiopulmonary,Exercise Testing, Cardiopulmonary,Exercise Tests,Exercise Tests, Cardiopulmonary,Fitness Testing, Physical,Fitness Testings,Step Tests,Stress Tests,Test Battery, Eurofit,Test, Arm Ergometry,Test, Bicycle Ergometry,Test, Cardiopulmonary Exercise,Test, EuroFit,Test, Exercise,Test, Step,Test, Stress,Test, Treadmill,Testing, Cardiopulmonary Exercise,Testing, Exercise,Testing, Fitness,Testing, Physical Fitness,Tests, Arm Ergometry,Tests, Bicycle Ergometry,Tests, Cardiopulmonary Exercise,Tests, EuroFit,Tests, Exercise,Tests, Step,Tests, Stress,Tests, Treadmill,Treadmill Tests
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Chabanier, and A Richard, and P Virot, and T Bontemps, and A Tardieu, and D Pinaud, and H Vergnoux, and P Blanc, and J Bensaïd
April 1982, The American journal of cardiology,
A Chabanier, and A Richard, and P Virot, and T Bontemps, and A Tardieu, and D Pinaud, and H Vergnoux, and P Blanc, and J Bensaïd
June 1988, The American journal of cardiology,
A Chabanier, and A Richard, and P Virot, and T Bontemps, and A Tardieu, and D Pinaud, and H Vergnoux, and P Blanc, and J Bensaïd
March 1982, Archives des maladies du coeur et des vaisseaux,
A Chabanier, and A Richard, and P Virot, and T Bontemps, and A Tardieu, and D Pinaud, and H Vergnoux, and P Blanc, and J Bensaïd
January 1972, Circulation,
A Chabanier, and A Richard, and P Virot, and T Bontemps, and A Tardieu, and D Pinaud, and H Vergnoux, and P Blanc, and J Bensaïd
January 1975, Cardiovascular clinics,
A Chabanier, and A Richard, and P Virot, and T Bontemps, and A Tardieu, and D Pinaud, and H Vergnoux, and P Blanc, and J Bensaïd
January 1976, Acta medica Scandinavica,
A Chabanier, and A Richard, and P Virot, and T Bontemps, and A Tardieu, and D Pinaud, and H Vergnoux, and P Blanc, and J Bensaïd
September 1979, European journal of clinical pharmacology,
A Chabanier, and A Richard, and P Virot, and T Bontemps, and A Tardieu, and D Pinaud, and H Vergnoux, and P Blanc, and J Bensaïd
January 1979, Journal of cardiovascular pharmacology,
A Chabanier, and A Richard, and P Virot, and T Bontemps, and A Tardieu, and D Pinaud, and H Vergnoux, and P Blanc, and J Bensaïd
March 1996, International journal of clinical pharmacology and therapeutics,
A Chabanier, and A Richard, and P Virot, and T Bontemps, and A Tardieu, and D Pinaud, and H Vergnoux, and P Blanc, and J Bensaïd
June 1983, Cardiologia (Rome, Italy),
Copied contents to your clipboard!